Amanda Morris, DO
Endocrinology, Diabetes & Metabolism · Saint Joseph, MINPI 1730479270
Payments from drug & device makers
Across 794 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$2K
- Xeris Pharmaceuticals, Inc.$2K
- Lilly USA, LLC$756
- AstraZeneca$651
- Sanofi-aventis U.S. LLC$498
- plus $6K from 42 others
What the payments were for
- Speaking & faculty fees$1,1009%
- Food & beverage$11,69990%
- Education$811%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,100
How this compares
$12,939 in reported general payments places this provider in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $524,419 |
| MounjaroTirzepatide | 276 | $365,875 |
| OzempicSemaglutide | 183 | $286,491 |
| RecorlevLevoketoconazole | 12 | $263,923 |
| TrulicityDulaglutide | 114 | $185,296 |
| FarxigaDapagliflozin Propanediol | 97 | $112,998 |
| JardianceEmpagliflozin | 82 | $106,619 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $102,648 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 107 | $88,948 |
| ForteoTeriparatide | 11 | $45,278 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $42,923 |
| Xigduo XrDapaglifloz Propaned/Metformin | 31 | $32,359 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $24,910 |
| WegovySemaglutide | 14 | $23,314 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $22,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $756 | $610,691456 claims |
| Corcept TherapeuticsKorlym | $304 | $524,41913 claims |
| Novo NordiskOzempic, Wegovy, Novolog | $1,819 | $324,948244 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $1,562 | $263,92312 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $445 | $172,473127 claims |
| AstraZenecaFarxiga | $651 | $112,99897 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $41 | $14,154793 claims |
| Johnson & JohnsonInvokana | $367 | $12,37316 claims |
| Sanofi-aventis U.S. LLCLantus, Admelog | $498 | $11,77644 claims |
| AbbVieSynthroid | $482 | $7,91369 claims |
| IBSA Pharma Inc.Tirosint | $47 | $5,13313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Saint Joseph
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.